Matthew S. Davids, MD

Dana-Farber Cancer Institute

Academic Titles

Associate Professor, Medicine, Harvard Medical School

Research Program Affiliation

Co-Leader, Lymphoma and Myeloma

Leadership Roles

Member, Center Scientific Council

Research Abstract

I lead an active translational research program in chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL), focusing on Bcl-2 biology in the laboratory and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL, NHL, and other hematologic malignancies. Much of my work has focused on Bcl-2 inhibition with venetoclax, BTK inhibition with ibrutinib, and checkpoint blockade as a way to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.